Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop bispecific cancer therapies leveraging CytomX's Probody® platform and Regeneron's Veloci-Bi® technology. CytomX will receive a $30 million upfront payment and could earn up to $2 billion in future milestone payments related to research and commercialization. The partnership aims to create conditionally activated therapies designed to minimize off-target effects, potentially benefiting tumor types unresponsive to current immunotherapy approaches.
Regeneron Pharmaceuticals and CytomX Therapeutics have entered a significant collaboration to develop next-generation bispecific immunotherapies. CytomX will receive an upfront payment of $30 million and could earn up to $2 billion in future milestones. The collaboration focuses on utilizing CytomX's Probody® technology and Regeneron's Veloci-Bi® platform to create therapies that activate specifically in tumor environments, potentially improving treatment efficacy and reducing side effects. The partnership aims to expand cancer treatment options significantly.
CytomX Therapeutics (CTMX) reported its Q3 2022 financial results and business updates, highlighting advancements in its oncology pipeline. The company is progressing on CX-2051 and CX-801, both slated for IND submissions in 2023. CX-904 is currently in Phase 1, while collaborations with Bristol Myers Squibb on BMS-986249 and AbbVie on CX-2029 continue in Phase 2. Financially, cash reserves decreased to $194.3 million from $305.2 million year-over-year, with revenue of $16.9 million. R&D expenses rose to $30.4 million, reflecting restructuring expenses.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming presentation of preclinical data for CX-801, a masked interferon alpha-2b therapeutic candidate, at the SITC Annual Meeting in Boston. CX-801 aims to improve tolerability and efficacy in treating tumors by leveraging a favorable therapeutic index. The company plans to file an IND for CX-801 in the second half of 2023, with ongoing exploration of its potential in both responsive and non-responsive tumor types. The presentation is scheduled for November 10-11, 2022, detailing the benefits of CX-801 combined with PD-L1 blockade.
CytomX Therapeutics (Nasdaq: CTMX) has announced participation in two key investor conferences in November. CEO Sean McCarthy will engage in a virtual fireside chat for the BMO Biopharma Spotlight Series: Oncology Day on November 9 at 11:30 a.m. ET, followed by a session at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 8:30 a.m. ET in New York. A live webcast will be available on CytomX’s website, where management will also hold one-on-one investor meetings.
CytomX Therapeutics (CTMX) will announce its third quarter 2022 financial results on November 8, 2022, after market close. Following the results, a conference call will be hosted at 5:00 p.m. ET to discuss the findings and provide updates. The company focuses on conditionally activated oncology therapeutics, with a pipeline including seven therapeutic candidates such as CX-2029 and Probody therapeutics partnered with leading biopharmaceutical companies. For further details, visit CytomX's website.
CytomX Therapeutics (NASDAQ: CTMX) announced the presentation of updated Phase 1 results for BMS-986249, its Probody therapeutic designed to target CTLA-4, at the ESMO 2022 Congress. Collaborator Bristol Myers Squibb reported encouraging findings, including a complete response in melanoma and a partial response in colorectal cancer. The ongoing Phase 2 trial aims to evaluate BMS-986249's efficacy against conventional ipilimumab. CytomX continues to advance a diverse pipeline of oncology candidates with multiple collaborations, enhancing its presence in the oncology market.
CytomX Therapeutics presented advancements in its ADC portfolio, particularly CX-2051, at the World ADC conference in San Diego on September 6-9, 2022. CX-2051 is a conditionally activated ADC, targeting EpCAM, aimed at improving treatment for EpCAM-expressing cancers. The payload is camptothecin, which has shown safe clinical activity. CytomX's strategy focuses on leveraging its Probody technology to enhance therapeutic efficacy while minimizing toxicity. Upcoming plans include submissions for investigational new drug applications in the latter half of 2023.
CytomX Therapeutics (CTMX) reported its Q2 2022 financial results, highlighting a strategic restructuring aimed at focusing on its early-stage pipeline and extending its cash runway to 2025. The company plans to submit INDs for two product candidates in 2023 and is advancing partnered clinical programs including CX-904 with Amgen and BMS-986249 with Bristol Myers Squibb. Cash and investments stood at $228 million, up from $16 million in revenue year-over-year. R&D expenses increased to $31 million, attributed to higher personnel costs.
CytomX Therapeutics (Nasdaq: CTMX), a leader in oncology therapeutics, announced CEO Sean McCarthy will participate in two investor conferences this August. The conferences are the BTIG Biotechnology Conference on August 9, 2022, and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, where he will take part in a panel discussion at 2:20 p.m. ET. A live webcast of the Wedbush panel will be available on CytomX’s website. The company focuses on conditionally activated biologics, with a robust pipeline including candidates for various cancers.